Intech Investment Management LLC Has $1.34 Million Stock Holdings in Guardant Health, Inc. (NASDAQ:GH)

Intech Investment Management LLC grew its holdings in Guardant Health, Inc. (NASDAQ:GH) by 33.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 43,824 shares of the company’s stock after buying an additional 10,976 shares during the quarter. Intech Investment Management LLC’s holdings in Guardant Health were worth $1,339,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Wellington Management Group LLP increased its position in Guardant Health by 188.6% in the third quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock worth $232,325,000 after purchasing an additional 6,618,785 shares during the period. Erste Asset Management GmbH acquired a new stake in Guardant Health in the third quarter worth about $21,389,000. Lord Abbett & CO. LLC acquired a new stake in Guardant Health in the third quarter worth about $15,624,000. Two Sigma Advisers LP increased its position in Guardant Health by 52.7% in the third quarter. Two Sigma Advisers LP now owns 1,177,300 shares of the company’s stock worth $27,007,000 after purchasing an additional 406,500 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in Guardant Health by 19.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company’s stock worth $44,732,000 after purchasing an additional 238,037 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GH has been the topic of a number of recent analyst reports. Guggenheim restated a “buy” rating and set a $56.00 target price on shares of Guardant Health in a report on Monday, February 24th. Barclays initiated coverage on Guardant Health in a report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 target price on the stock. The Goldman Sachs Group raised their target price on Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Scotiabank raised their target price on Guardant Health from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Monday, February 24th. Finally, Morgan Stanley raised their target price on Guardant Health from $42.00 to $52.00 and gave the stock an “overweight” rating in a report on Thursday, March 6th. Twenty analysts have rated the stock with a buy rating, According to data from MarketBeat, Guardant Health has an average rating of “Buy” and an average price target of $48.40.

Guardant Health Stock Performance

NASDAQ GH opened at $46.10 on Friday. The stock has a market capitalization of $5.69 billion, a price-to-earnings ratio of -12.95 and a beta of 1.50. The stock’s 50 day moving average price is $43.85 and its two-hundred day moving average price is $33.50. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $50.89.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The company had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. On average, equities research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.